Based on our results that ASAH1 regulates MAPK pathway, we investigated whether the MAPK pathway inhibitor trametinib, an MEK inhibitor, can exert a tumor-suppressive effect in TNBC cells, similar to that observed for the ASAH1 inhibitor carmofur. Here, MAP2K7 is linked to neoplasm.